Bromantane (25mg/capsule), 60 Capsules

Bromantane exhibits a distinct pharmacological profile characterized by interactions with monoamine transporter systems together with modulation of enzymes involved in monoamine-associated signaling pathways, including tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD). These properties make Bromantane a useful research tool for investigating transporter pharmacology, enzyme regulation, transcriptional control mechanisms, and the relationship between transporter activity and biosynthetic pathway modulation

The adamantane scaffold provides a rigid three-dimensional molecular framework that influences physicochemical properties, target interactions, and structure-activity relationships. Bromantane's halogenated adamantane structure has made it a valuable compound for investigating how scaffold architecture affects transporter interactions, signaling pathway activity, and ligand-receptor pharmacology.

Research applications frequently include comparative analyses of adamantane-derived compounds and their distinct molecular interaction profiles.

Experimental investigations have reported interactions with dopamine transporter (DAT) and serotonin transporter (SERT) systems together with modulation of regulatory enzymes associated with monoaminergic signaling networks. These characteristics have established Bromantane as a useful research tool for examining transporter-enzyme relationships, signal transduction mechanisms, transcriptional regulatory processes, and molecular pathways associated with monoamine system function.